1. Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax 2019;74(Suppl 1):1–69.
2. McDonnell MJ, Ward C, Rutherford RM. 4. Comorbidities and their impactIn: Chalmers JD, Polverino E, Aliberti S, eds. Bronchiectasis. Sheffield: ERS Publications, 2018:45–61.
4. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J 2009;33:897–906.
7. Lee H, Choi H, Chalmers JD, et al. Characteristics of bronchiectasis in Korea: first data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology 2021;26:619–621.
12. Kim NY, Lee CH, Jin KN, et al. Clinical deterioration and lung function change in patients with concomitant asthma and bronchiectasis. J Allergy Clin Immunol Pract 2022 Jun 9 [Epub].
https://doi.org/10.1016/j.jaip.2022.05.026
17. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017;50:1700629.
19. Carpagnano GE, Scioscia G, Lacedonia D, Curradi G, Foschino Barbaro MP. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy 2019;12:83–90.
20. Crimi C, Campisi R, Nolasco S, et al. Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study. Respir Med 2021;185:106491.
22. Crimi C, Campisi R, Cacopardo G, et al. Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis. Eur Respir J 2019;54(Suppl 63):PA2528.
24. Aliberti S, Sotgiu G, Blasi F, Saderi L, Posadas T, Martinez Garcia MA. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J 2020;56:2000453.
26. Zhu YN, Xie JQ, He XW, et al. Prevalence and clinical characteristics of nontuberculous mycobacteria in patients with bronchiectasis: a systematic review and meta-analysis. Respiration 2021;100:1218–1229.
27. Yang B, Ryu J, Kim T, et al. Impact of bronchiectasis on incident nontuberculous mycobacterial pulmonary disease: a 10-year national cohort study. Chest 2021;159:1807–1811.
28. Lee JY, Song JW, Hong SB, et al. Prevalence of NTM pulmonary infection in the patients with bronchiectasis. Tuberc Respir Dis 2004;57:311–319.
30. Chung WS, Lin CL, Hsu WH, Kao CH. Increased risk of lung cancer among patients with bronchiectasis: a nationwide cohort study. QJM 2016;109:17–25.
35. Alzeer AH, Al-Mobeirek AF, Al-Otair HA, Elzamzamy UA, Joherjy IA, Shaffi AS. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest 2008;133:468–473.
36. Devaraj A, Wells AU, Meister MG, Loebinger MR, Wilson R, Hansell DM. Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. AJR Am J Roentgenol 2011;196:1300–1304.
37. McDonnell MJ, O'Toole D, Ward C, et al. A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: current understanding and future risk. Respir Med 2018;141:132–143.
38. McDonnell MJ, Ahmed M, Das J, et al. Hiatal hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis. Respirology 2015;20:749–757.
39. Mandal P, Morice AH, Chalmers JD, Hill AT. Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis. Respir Med 2013;107:1008–1013.
42. Wilczynska MM, Condliffe AM, McKeon DJ. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir Care 2013;58:694–701.
43. Martin LW, Prisco LC, Huang W, et al. Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2021;51:1067–1080.
44. Swinson DR, Symmons D, Suresh U, Jones M, Booth J. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997;36:689–691.
45. De Soyza A, McDonnell MJ, Goeminne PC, et al. Bronchiectasis rheumatoid overlap syndrome is an independent risk factor for mortality in patients with bronchiectasis: a multicenter cohort study. Chest 2017;151:1247–1254.
46. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993;72:151–183.
47. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007;131:524–532.
48. Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J 2000;15:5–10.
49. Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000;15:41–48.
50. Kelly MG, Frizelle FA, Thornley PT, Beckert L, Epton M, Lynch AC. Inflammatory bowel disease and the lung: is there a link between surgery and bronchiectasis? Int J Colorectal Dis 2006;21:754–757.
51. Gülhan PY, Bulcun E, Gülhan M, Çimen D, Ekici A, Ekici M. Low cognitive ability in subjects with bronchiectasis. Respir Care 2015;60:1610–1615.
54. Shteinberg M, Goeminne P, Loebinger M, et al. Rhinosinusitis is associated with increased symptoms and more frequent exacerbations among patients with bronchiectasis- data from the EMBARC registry. Eur Respir J 2018;52(Suppl 62):PA350.
55. Yu I, Yong SJ, Lee WY, et al. Prevalence of chronic rhinosinusitis and its relating factors in patients with bronchiectasis: findings from KMBARC registry. Korean J Intern Med 2022;[In press].